Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Dougan

Showing results (21-30 of 145) with videos related to

Pageof 15
Sort By:
Nature Medicine|July 5, 2019
Programmable bacteria as cancer therapyMichael Dougan, Stephanie K Dougan
The Oncologist|June 2, 2018
Diagnosis and Management of Hepatitis in Patients on Checkpoint BlockadeKerry Reynolds, Molly Thomas, Michael Dougan
Immunity|April 18, 2019
GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of InflammationMichael Dougan, Glenn Dranoff, Stephanie K Dougan
Annual Review of Cancer Biology|August 4, 2023
Cancer Immunotherapy: Beyond Checkpoint BlockadeMichael Dougan, Glenn Dranoff, Stephanie K Dougan
Expert Review of Anticancer Therapy|July 30, 2020
Immune-related adverse events: what we've learned and where we're headingYousef R Badran, Donna E Leet, Michael Dougan
NEJM Evidence|May 28, 2024
Leaping toward ToleranceSarita U Patil, Stephanie K Dougan, Michael Dougan
Trends in Cancer|April 28, 2023
Immune mechanisms of toxicity from checkpoint inhibitorsS Jennifer Wang, Stephanie K Dougan, Michael Dougan
Cell|August 9, 2024
Anti-LAG-3 boosts CD8 T cell effector functionCourtney T Kureshi, Michael Dougan, Stephanie K Dougan
Current Gastroenterology Reports|October 20, 2022
Update on Immune Checkpoint Inhibitor EnterocolitisMolly R Kelly-Goss, Yousef R Badran, Michael Dougan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2020
Reply to Y. Inagaki et alHamzah Abu-Sbeih, David M Faleck, Michael Dougan, et al.
Pageof 15

Showing results (21-30 of 145) with videos related to

Sort By:
Pageof 15
Nature Medicine|July 5, 2019
Programmable bacteria as cancer therapyMichael Dougan, Stephanie K Dougan
The Oncologist|June 2, 2018
Diagnosis and Management of Hepatitis in Patients on Checkpoint BlockadeKerry Reynolds, Molly Thomas, Michael Dougan
Immunity|April 18, 2019
GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of InflammationMichael Dougan, Glenn Dranoff, Stephanie K Dougan
Annual Review of Cancer Biology|August 4, 2023
Cancer Immunotherapy: Beyond Checkpoint BlockadeMichael Dougan, Glenn Dranoff, Stephanie K Dougan
Expert Review of Anticancer Therapy|July 30, 2020
Immune-related adverse events: what we've learned and where we're headingYousef R Badran, Donna E Leet, Michael Dougan
NEJM Evidence|May 28, 2024
Leaping toward ToleranceSarita U Patil, Stephanie K Dougan, Michael Dougan
Trends in Cancer|April 28, 2023
Immune mechanisms of toxicity from checkpoint inhibitorsS Jennifer Wang, Stephanie K Dougan, Michael Dougan
Cell|August 9, 2024
Anti-LAG-3 boosts CD8 T cell effector functionCourtney T Kureshi, Michael Dougan, Stephanie K Dougan
Current Gastroenterology Reports|October 20, 2022
Update on Immune Checkpoint Inhibitor EnterocolitisMolly R Kelly-Goss, Yousef R Badran, Michael Dougan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2020
Reply to Y. Inagaki et alHamzah Abu-Sbeih, David M Faleck, Michael Dougan, et al.
Pageof 15